title: Improving pediatric asthma patient outcomes by incorporation of effective interventions.
abstract: Asthma affects approximately 5 million children in the United States. This disease results in billions of dollars of expenditures for hospitalizations, emergency admissions, medications, equipment, and indirect costs such as lost work productivity. This article describes how children with asthma received in-depth evaluations and education, long-term control medications, and Air Watch monitoring to improve treatment adherence, asthma control, and asthma severity. Study patients (n = 99) received patient care and education according to the protocols of the Pediatric Asthma Clinic, Lovelace Health Systems (Albuquerque, NM). All enrolled patients were prescribed fluticasone propionate and salmeterol xinafoate based on asthma severity and the National Institutes of Health guidelines. In addition, each patient used the AirWatch electronic airway monitoring system. Patients (n = 80) who participated in the study for 6 months demonstrated overall improved adherence to prescribed medications and better control of asthma. Adherence to the AirWatch system decreased over time, most likely due to improvements in the way the patients felt. In conclusion, treatment adherence, asthma control, and asthma severity can be improved with comprehensive patient education, long-term control medications, and objective home pulmonary function monitoring.
authors.affiliation: Lovelace Health Systems, Albuquerque, New Mexico, USA. alice.marosi@lovelace.com
authors.forename: A
authors.initials: A
authors.lastname: Marosi
authors.forename: J
authors.initials: J
authors.lastname: Stiesmeyer
mesh_terms: D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D010349:Patient Compliance; D010353:Patient Education as Topic; D010366:Peak Expiratory Flow Rate; D000068299:Salmeterol Xinafoate; D012720:Severity of Illness Index
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol